{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:28:31Z","timestamp":1793035711865,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T00:00:00Z","timestamp":1556841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00431-019-03384-x","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T21:06:40Z","timestamp":1556917600000},"page":"1013-1021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial"],"prefix":"10.1007","volume":"178","author":[{"given":"Franz","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djalila","family":"Mekahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Emma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney D.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Bockenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Cadnapaphornchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Dandurand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Sikes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Shoaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"key":"3384_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/MOP.0000000000000195","volume":"27","author":"MA Cadnapaphornchai","year":"2015","unstructured":"Cadnapaphornchai MA (2015) Autosomal dominant polycystic kidney disease in children. Curr Opin Pediatr 27:193\u2013200","journal-title":"Curr Opin Pediatr"},{"key":"3384_CR2","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2215\/CJN.02810608","volume":"4","author":"MA Cadnapaphornchai","year":"2009","unstructured":"Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW (2009) Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4:820\u2013829","journal-title":"Clin J Am Soc Nephrol"},{"key":"3384_CR3","unstructured":"ClinicalTrials.gov (2019) Safety, pharmacokinetics, tolerability and efficacy of tolvaptan in children and adolescents with ADPKD (autosomal dominant polycystic kidney disease) [\n                    ClinicalTrials.gov\n                    \n                   identifier: NCT02964273]. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02964273\n                    \n                  . Accessed 29 Mar 2019"},{"key":"3384_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","volume":"2","author":"O Devuyst","year":"2017","unstructured":"Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD (2017) Tolerability of aquaretic-related symptoms following tolvaptan therapy in subjects with autosomal dominant polycystic kidney disease: results from TEMPO 3:4. Kidney Int Rep 2:1132\u20131140","journal-title":"Kidney Int Rep"},{"key":"3384_CR5","unstructured":"EU Clinical Trials Register (2019) A phase 3b, two-part, multicenter, one year randomized, double-blind, placebo-controlled trial of the safety, pharmacokinetics, tolerability, and efficacy of tolvaptan followed by a two year open-label extension in children and adolescent subjects with autosomal dominant polycystic kidney disease (ADPKD) [EudraCT number: 2016-000187-42]. \n                    https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-000187-42\/GB\/\n                    \n                  . Accessed 29 Mar 2019"},{"key":"3384_CR6","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1046\/j.1523-1755.2001.0590051654.x","volume":"59","author":"GM Fick-Brosnahan","year":"2001","unstructured":"Fick-Brosnahan GM, Tran ZV, Johnson AM, Strain JD, Gabow PA (2001) Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int 59:1654\u20131662","journal-title":"Kidney Int"},{"key":"3384_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00467-017-3584-9","volume":"32","author":"RD Gilbert","year":"2017","unstructured":"Gilbert RD, Evans H, Olalekan K, Nagra A, Haq MR, Griffiths M (2017) Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease. Pediatr Nephrol 32:893\u2013896","journal-title":"Pediatr Nephrol"},{"key":"3384_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1681\/ASN.2007101100","volume":"19","author":"JJ Grantham","year":"2008","unstructured":"Grantham JJ (2008) Therapy for polycystic kidney disease? It\u2019s water, stupid! J Am Soc Nephrol 19:1\u20137","journal-title":"J Am Soc Nephrol"},{"key":"3384_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2215\/CJN.00330705","volume":"1","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Chapman AB, Torres VE et al (2006) Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 1:148\u2013157","journal-title":"Clin J Am Soc Nephrol"},{"key":"3384_CR10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nrneph.2011.109","volume":"7","author":"JJ Grantham","year":"2011","unstructured":"Grantham JJ, Mulamalla S, Swenson-Fields KI (2011) Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 7:556\u2013566","journal-title":"Nat Rev Nephrol"},{"key":"3384_CR11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2215\/CJN.00780110","volume":"5","author":"KL Lentine","year":"2010","unstructured":"Lentine KL, Xiao H, Machnicki G, Gheorghian A, Schnitzler MA (2010) Renal function and healthcare costs in patients with polycystic kidney disease. Clin J Am Soc Nephrol 5:1471\u20131479","journal-title":"Clin J Am Soc Nephrol"},{"key":"3384_CR12","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2215\/CJN.11401017","volume":"13","author":"L Massella","year":"2018","unstructured":"Massella L, Mekahli D, Paripovic D et al (2018) Prevalence of hypertension in children with early-stage ADPKD. Clin J Am Soc Nephrol 13:874\u2013883","journal-title":"Clin J Am Soc Nephrol"},{"key":"3384_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/2229-3485.173781","volume":"7","author":"V Ruikar","year":"2016","unstructured":"Ruikar V (2016) Interactive Voice\/Web Response System in clinical research. Perspect Clin Res 7:15\u201320","journal-title":"Perspect Clin Res"},{"key":"3384_CR14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1681\/ASN.2005070697","volume":"17","author":"AD Rule","year":"2006","unstructured":"Rule AD, Torres VE, Chapman AB et al (2006) Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol 17:854\u2013862","journal-title":"J Am Soc Nephrol"},{"key":"3384_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637","journal-title":"J Am Soc Nephrol"},{"key":"3384_CR16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/jcph.880","volume":"57","author":"SE Shoaf","year":"2017","unstructured":"Shoaf SE, Chapman AB, Torres VE, Ouyang J, Czerwiec FS (2017) Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial. J Clin Pharmacol 57:906\u2013917","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 4","key":"3384_CR17","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","volume":"29","author":"EM Spithoven","year":"2014","unstructured":"Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, Areste N, Alonso de la Torre R, Caskey F, Couchoud C, Finne P, Heaf J, Hoitsma A, de Meester J, Pascual J, Postorino M, Ravani P, Zurriaga O, Jager KJ, Gansevoort RT, on behalf of the ERA-EDTA Registry, de los Angeles Garcia Bazaga M, Metcalfe W, Rodrigo E, Quiros JR, the EuroCYST Consortium, Budde K, Devuyst O, Ecder T, Eckardt KU, Gansevoort RT, Kottgen A, Ong AC, Petzold K, Pirson Y, Remuzzi G, Torra R, Sandford RN, Serra AL, Tesar V, Walz G, the WGIKD, Wuthrich RP, Antignac C, Bindels R, Chauveau D, Devuyst O, Emma F, Gansevoort RT, Maxwell PH, Ong AC, Remuzzi G, Ronco P, Schaefer F, ERA-EDTA Registry, EuroCYST Consortium, WGIKD (2014) Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant 29(Suppl 4):iv15\u2013iv25","journal-title":"Nephrol Dial Transplant"},{"key":"3384_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y (2007) Autosomal dominant polycystic kidney disease. Lancet 369:1287\u20131301","journal-title":"Lancet"},{"key":"3384_CR19","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS (2012) TEMPO 3:4 Trial Investigators (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407\u20132418","journal-title":"N Engl J Med"},{"key":"3384_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2215\/CJN.06300615","volume":"11","author":"VE Torres","year":"2016","unstructured":"Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, TEMPO 3:4 Trial Investigators (2016) Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol 11:803\u2013811","journal-title":"Clin J Am Soc Nephrol"},{"key":"3384_CR21","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377:1930\u20131942","journal-title":"N Engl J Med"},{"key":"3384_CR22","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"PB Watkins","year":"2015","unstructured":"Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA (2015) Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf 38:1103\u20131113","journal-title":"Drug Saf"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-019-03384-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00431-019-03384-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-019-03384-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T23:14:58Z","timestamp":1588374898000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-019-03384-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["3384"],"URL":"https:\/\/doi.org\/10.1007\/s00431-019-03384-x","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]},"assertion":[{"value":"6 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FS has received fees for serving on Otsuka advisory boards. DM has received a research grant from Otsuka and serves on an Otsuka advisory board. FE has received fees as a member of the Otsuka safety committee for pediatric studies. RDG has nothing to disclose. DB has received consultation fees from Otsuka. MAC has served as a consultant to Otsuka. LS, AD, KS, and SES are employees of Otsuka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}